Longeveron Inc. LGVN
1.78 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
1.78 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
1.75 Day range 1.82
1.31 52-week range 12.30
- YTD
- -64.82%
- 1 year
- -77.75%
- Market cap
- 5.67M
- Revenue (ttm)
- 1.23M
- EPS (ttm)
- -9.90
- Shares out
- 13.35M
- Forward P/E
- -1.16
- YTD return
- -64.82%
- 1-year return
- -77.75%
- Volume
- 61.41K
- Avg volume
- 106.52K
- Open
- 1.76
- Previous close
- 1.78
- Day's range
- 1.75 – 1.82
- 52-week range
- 1.31 – 12.30
- Beta
- 0.35
- Price target
- 8.88 (+398.6%)
- Earnings date
- Aug 14, 2024
MAX -739.22 (-99.76%)
Key statistics
- Enterprise value
- 22.40M
- PEG ratio
- 0.00
- Price / sales
- 21.37
- Price / book
- 0.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 115.70%
- Free cash flow
- -10.03M
- Total cash
- 12.38M
- Total debt
- 1.75M
- Return on equity
- -142.16%
- Short % of float
- 10.24%
- 50-day average
- 2.01
- 200-day average
- 2.26
Analyst view
Price target (mean) 8.88 +398.6% upside
Now 1.78
- Target (low)
- 6.00
- Target (mean)
- 8.88
- Target (high)
- 10.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy3
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
LGVN Revenue — quarterly 287.00K
LGVN Net income — quarterly -6.07M
LGVN EPS — quarterly -1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.53 | -0.34 | +0.19 | +35.85% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | -1.83 | -0.80 | -77.67% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -2.01 | -1.61 | +0.40 | +19.90% |
| May 14, 2024 | Mar 1, 2024 | -2.01 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -2.10 | -2.50 | -0.40 | -19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 27, 2024 | Maxim Group | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- longeveron.com
News
Longeveron Announces Engagement of Lucid Capital Markets 
Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome 
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Longeveron to Participate in Three Longevity/Aging Investment Conferences 
12 Health Care Stocks Moving In Friday's Intraday Session - 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Why Generac Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket 
Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why
Your note
Sign in to keep a note on LGVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAFONOVA NATALIYA | Officer | Stock Award(Grant) | Aug 14, 2024 | 163,130 |
| BALUCH KHOSO | Director | Sale | Dec 1, 2024 | 23,750 |
| HARE JOSHUA M | Officer, Director and Beneficial Owner | Stock Award(Grant) | Aug 14, 2024 | 727,046 |
| HARE NEIL E | Director | Stock Award(Grant) | Aug 14, 2024 | 30,246 |
| HASHAD MOHAMED WA'EL AHMED | Chief Executive Officer | Stock Award(Grant) | Aug 14, 2024 | 90,368 |
| KENDER RICHARD N | Director | Stock Award(Grant) | May 9, 2024 | 16,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.97% | 128,947 | 228.24K | Sep 29, 2024 |
| Vanguard Group Inc | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Capital Investment Advisory Services, LLC | 0.20% | 26,525 | 46.95K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 15,180 | 26.87K | Sep 29, 2024 |
| Creative Planning | 0.08% | 11,200 | 19.82K | Sep 29, 2024 |
| Blackrock Inc. | 0.08% | 10,016 | 17.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 72,197 | 127.79K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 24,137 | 42.72K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 17,087 | 30.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,572 | 6.32K | Oct 30, 2024 |